Agile Therapeutics Q3 Adjusted EPS $(1.47) Beats $(1.84) Estimate, Sales $6.66M Beat $5.27M Estimate
Portfolio Pulse from Benzinga Newsdesk
Agile Therapeutics reported Q3 adjusted EPS of $(1.47), beating the estimate of $(1.84) by 20.11%. The company also reported sales of $6.66M, surpassing the estimate of $5.27M by 26.41%. This represents a 87.22% increase in EPS and a 121.92% increase in sales compared to the same period last year.
November 09, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agile Therapeutics reported better than expected Q3 results, which could positively impact the stock.
Agile Therapeutics reported better than expected earnings and sales for Q3. This positive financial performance could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100